Using the SF-36 measure to compare the health impact of multiple sclerosis and Parkinson's disease with normal population health profiles.
about
Deep Brain Stimulation for Parkinson's Disease with Early Motor Complications: A UK Cost-Effectiveness AnalysisYoga for multiple sclerosis: a systematic review and meta-analysisAssessing function and endurance in adults with spinal and bulbar muscular atrophy: validity of the adult myopathy assessment tool.Long-term natalizumab treatment is associated with sustained improvements in quality of life in patients with multiple sclerosis.Psychometric properties of the patient activation measure among multimorbid older adults.Risk of sleep-disordered breathing in Parkinson's diseaseV-TIME: a treadmill training program augmented by virtual reality to decrease fall risk in older adults: study design of a randomized controlled trial.Quality of life outcomes with BG-12 (dimethyl fumarate) in patients with relapsing-remitting multiple sclerosis: the DEFINE study.Clinical features of spinal and bulbar muscular atrophy.Quality of life measures for the palliative care of people severely affected by multiple sclerosis: a systematic review.The effect of deep brain stimulation on quality of life in movement disorders.Health Related Quality of Life in a Dutch Rehabilitation Population: Reference Values and the Effect of Physical ActivityImpact of natalizumab on patient-reported outcomes in multiple sclerosis: a longitudinal studyCarer quality of life and experiences of health services: a cross-sectional survey across three neurological conditions.Declining quality of life in Parkinson disease before and after diagnosis.SF-36 includes less Parkinson Disease (PD)-targeted content but is more responsive to change than two PD-targeted health-related quality of life measures.The cost-effectiveness of deep brain stimulation in combination with best medical therapy, versus best medical therapy alone, in advanced Parkinson's diseaseEmployment and multiple sclerosis: A meta-analytic review of psychological correlates.Health-Related Quality of Life in Patients with Multiple Sclerosis: Impact of Disease-Modifying Drugs.Validation of the Oxford Participation and Activities Questionnaire.A short and validated multiple sclerosis-specific health-related quality of life measurement for routine medical practice.Type D, anxiety and depression in association with quality of life in patients with Parkinson's disease and patients with multiple sclerosis.Patients' experiences of health and social care in long-term neurological conditions in England: a cross-sectional survey.Predictors of deterioration in health-related quality of life in Parkinson's disease: results from the DATATOP trial.Health-related quality of life in patients with relapsing-remitting multiple sclerosis treated with subcutaneous interferon β-1a in Iran.Health-related quality of life in multiple sclerosis: role of cognitive appraisals of self, illness and treatment.Meanings, motivations, and strategies for engaging in physical activity among women with multiple sclerosis.Change in quality of life and predictors of change among patients with multiple sclerosis: a prospective cohort study.The effects of clinical interventions on health-related quality of life in multiple sclerosis: a meta-analysis.Exercise in the community for people with minimal gait impairment due to MS: an assessor-blind randomized controlled trial.The scope and nature of pain in persons with multiple sclerosis.Impact of walking impairment in multiple sclerosis: perspectives of patients and care partners.Intramuscular interferon beta-1a therapy in patients with relapsing-remitting multiple sclerosis: a 15-year follow-up study.Gender differences in health-related quality of life in multiple sclerosis.Health-related quality of life in patients with hereditary spastic paraplegia in Estonia.Illness perception and health-related quality of life in multiple sclerosis.Quality of life in Friedreich ataxia: what clinical, social and demographic factors are important?Change in quality of life in patients with relapsing-remitting multiple sclerosis over 2 years in relation to other clinical parameters: results from a trial of intramuscular interferon {beta}-1a.Association between age associated cognitive decline and health related quality of life among Iranian older individuals.
P2860
Q26779605-F80BA1CC-5EAC-48B3-864F-BC90F34DCD67Q27027450-B4ECB800-3870-486E-B19B-8F97A0588F27Q33634876-6747EC83-A900-49F4-85FF-D8AA62C2D735Q33825885-8E4ADCCB-7C54-445B-95A2-0373432CD639Q34150761-608C5FE5-BB05-4D7D-AF66-8D835C820668Q34299945-22CF41F9-7E6F-47F6-977D-3AB859F60249Q34578767-673ACA64-587C-42AE-8A9C-9F14D041C5DAQ34656851-5D74316E-A66A-41AE-A75B-1B3835C48D4BQ35008921-DC5C8D17-C9E3-439A-989D-A5B52E2EB861Q35976064-7C1A9DA4-18B5-4B8D-BEFB-7EB0E3AEBCF4Q36233666-7A8283FB-39D2-46B5-BCBA-48BDFFBEC186Q36242906-43EDDD5A-3A45-4B08-B37B-D6825AA26144Q36526965-15180DB2-62C4-4531-94DF-505D56080731Q36972607-145637CA-489B-4A19-8BF6-3C88191D2EA6Q37096777-4F4BA7F2-9AA3-4352-AF5A-ABBEEA335BE5Q37381351-325FA8EA-BE27-4067-806B-60C89339B82CQ37491322-E6D07D4D-FDB5-4343-99FE-223B7C46663AQ38623652-63F8304B-2C39-457B-AA67-7868C0C9B842Q38728373-118682CC-BBD6-4A41-8C85-C45FDF20E960Q41873836-AAF0D374-66E6-4055-B589-5019687B0E0BQ45343221-1E335D6C-6445-4053-9AC7-F30ECD3A9462Q45375629-A57A4494-0269-476C-BBC0-8198193B3256Q45966191-94643415-1EF1-4674-BA7B-6057C9E00F66Q46853430-EAB70D32-6D7A-4BAC-A547-E903D559A132Q47729046-407105B4-B173-4128-86FE-3ED7F53BE2D8Q47880981-290345E3-57B3-4E06-9C7C-178F9D3EFDD5Q47993563-59AF641C-3DEF-4C93-B841-E3BB4F3AF734Q48159747-CAFA4F11-06AE-47E1-B0C2-09A4099EE6EAQ48337817-87C64D9C-6452-41C5-A91F-F4322CE28BEAQ48360529-D975D4E8-6308-438E-A8D5-6B66FD95AC1CQ48486061-A899C5E0-B862-4B8A-B70A-7E64422EE0BFQ48628475-30D81012-A8A8-4340-8C28-E9BDD84675DAQ48881943-DD75EC09-3C36-4EDD-AA19-FD4810B789ACQ49011602-B4804E1C-0229-4159-ABAF-8EAF9EC6075FQ51850725-6EEBF69E-9323-4881-9EE9-CA00776D33A3Q51899512-66F6A7CF-FBFF-4C15-AA6C-14DBF05E30A4Q51900156-946F8F96-1118-4DC1-A21D-BEE14D283C61Q53051361-1A39C24F-3A12-4B88-9FD4-5919433E0D7AQ55004019-17322E0B-143B-4C37-9330-6D4E95524B08
P2860
Using the SF-36 measure to compare the health impact of multiple sclerosis and Parkinson's disease with normal population health profiles.
description
2003 nî lūn-bûn
@nan
2003 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
Using the SF-36 measure to com ...... al population health profiles.
@ast
Using the SF-36 measure to com ...... al population health profiles.
@en
type
label
Using the SF-36 measure to com ...... al population health profiles.
@ast
Using the SF-36 measure to com ...... al population health profiles.
@en
prefLabel
Using the SF-36 measure to com ...... al population health profiles.
@ast
Using the SF-36 measure to com ...... al population health profiles.
@en
P2093
P2860
P356
P1476
Using the SF-36 measure to com ...... al population health profiles.
@en
P2093
A J Thompson
C Jenkinson
D L Lamping
J A Freeman
J C Hobart
R Fitzpatrick
P2860
P304
P356
10.1136/JNNP.74.6.710
P407
P577
2003-06-01T00:00:00Z